Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis

Journal of Hepatology

Volumn 56, Issue 3, 2012, Pages 571-578

  Cárdenas, Andrés ^a,b   Gins, Pere ^a,b   Marotta, Paul ^c   Czerwiec, Frank ^d   Oyuang, John ^d   Guevara, Mónica ^a,b   Afdhal, Nezam H ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antidiuretic hormone; Arginine vasopressin; Ascites; Chronic liver disease; Cirrhosis; Dilutional hyponatremia; Edema; Vaptans

Indexed keywords

ALCOHOL; CREATININE; FUROSEMIDE; PLACEBO; SODIUM; SPIRONOLACTONE; TOLVAPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASCITES; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGEAL VARICE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HEALTH SURVEY; HEART ARREST; HEART RATE; HEMORRHOID; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NOCTURIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY FAILURE; SHORT FORM 12; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; XEROSTOMIA;

ADMINISTRATION, ORAL; ASCITES; BENZAZEPINES; CHRONIC DISEASE; FEMALE; HEALTH SURVEYS; HUMANS; HYPONATREMIA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, VASOPRESSIN; RECURRENCE; SODIUM; TREATMENT OUTCOME;

EID: 84857368395     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.08.020     Document Type: Article

References (22)

1. P. Gins, T. Berl, M. Bernardi, D.G. Bichet, G. Hamon, and W. Jimenez Hyponatremia in cirrhosis: from pathogenesis to treatment Hepatology 28 1998 851 864
2. A. Cárdenas, and P. Gins Sodium balance in cirrhosis M. Burnier, Sodium in Health and Disease 2008 Informa Healthcare New York 317 332
3. P. Gins, and M. Guevara Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management Hepatology 48 2008 1002 1010
4. W.R. Kim, S.W. Biggins, W.K. Kremers, R.H. Wiesner, P.S. Kamath, and J.T. Benson Hyponatremia and mortality among patients on the liver-transplant waiting list N Engl J Med 359 2008 1018 1026
5. M. Guevara, M.E. Baccaro, A. Torre, B. Gomez-Anson, J. Rios, and F. Torres Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis Am J Gastroenterol 104 2009 1382 1389
6. J.G. Verbalis, S.R. Goldsmith, A. Greenberg, R.W. Schrier, and R.H. Sterns Hyponatremia treatment guidelines 2007: expert panel recommendations Am J Med 120 2007 S1 21
7. A.L. Gerbes, V. Gulberg, P. Gins, G. Decaux, P. Gross, and H. Gandjini Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial Gastroenterology 124 2003 933 939
8. A. Troyer, W. Pilloy, I. Broeckaert, and J.C. Demanet Letter: demeclocycline treatment of water retention in cirrhosis Ann Intern Med 85 1976 336 337
9. F. Carrilho, J. Bosch, V. Arroyo, A. Mas, J. Viver, and J. Rodes Renal failure associated with demeclocycline in cirrhosis Ann Intern Med 87 1977 195 197
10. G. Decaux, P. Mols, P. Cauchie, B. Flamion, and F. Delwiche Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea Nephron 44 1986 337 343
11. G. Decaux, A. Soupart, and G. Vassart Non-peptide arginine-vasopressin antagonists: the vaptans Lancet 371 2008 1624 1632
12. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, and K. Swedberg Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 2007 1319 1331
13. R.W. Schrier, P. Gross, M. Gheorghiade, T. Berl, J.G. Verbalis, and F.S. Czerwiec Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 2006 2099 2112
14. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects, 2008.
15. J. Ware Jr., M. Kosinski, and S.D. Keller A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity Med Care 34 1996 220 233
16. J.E. Ware, M. Kosinski, and S.D. Keller SF-12®: how to score the SF-12® physical and mental health summary scales 2nd ed. 1995 The Health Institute, New England Medical Center Boston, MA
17. P. Gins, F. Wong, H. Watson, S. Milutinovic, L.R. del Arbol, and D. Olteanu Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial Hepatology 48 2008 204 213
18. P.J. Thuluvath, A. Maheshwari, F. Wong, H.W. Yoo, R.W. Schrier, and C. Parikh Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study Aliment Pharmacol Ther 24 2006 973 982
19. F. Wong, A.T. Blei, L.M. Blendis, and P.J. Thuluvath A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial Hepatology 37 2003 182 191
20. K. Okita, I. Sakaida, M. Okada, A. Kaneko, K. Chayama, and M. Kato A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis J Gastroenterol 45 2010 979 987
21. J.G. O'Leary, and G.L. Davis Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease Liver Transpl 15 2009 1325 1329
22. T. Berl, F. Quittnat-Pelletier, J.G. Verbalis, R.W. Schrier, D.G. Bichet, and J. Ouyang Oral tolvaptan is safe and effective in chronic hyponatremia J Am Soc Nephrol 21 2010 705 712